These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
445 related articles for article (PubMed ID: 19540888)
1. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. Hatakeyama H; Ito E; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H J Control Release; 2009 Oct; 139(2):127-32. PubMed ID: 19540888 [TBL] [Abstract][Full Text] [Related]
2. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Hatakeyama H; Akita H; Ito E; Hayashi Y; Oishi M; Nagasaki Y; Danev R; Nagayama K; Kaji N; Kikuchi H; Baba Y; Harashima H Biomaterials; 2011 Jun; 32(18):4306-16. PubMed ID: 21429576 [TBL] [Abstract][Full Text] [Related]
3. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. Sato Y; Hatakeyama H; Sakurai Y; Hyodo M; Akita H; Harashima H J Control Release; 2012 Nov; 163(3):267-76. PubMed ID: 23000694 [TBL] [Abstract][Full Text] [Related]
4. Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. Akita H; Kogure K; Moriguchi R; Nakamura Y; Higashi T; Nakamura T; Serada S; Fujimoto M; Naka T; Futaki S; Harashima H J Control Release; 2010 May; 143(3):311-7. PubMed ID: 20080139 [TBL] [Abstract][Full Text] [Related]
5. Octaarginine- and pH sensitive fusogenic peptide-modified nanoparticles for liver gene delivery. Khalil IA; Hayashi Y; Mizuno R; Harashima H J Control Release; 2011 Dec; 156(3):374-80. PubMed ID: 21864599 [TBL] [Abstract][Full Text] [Related]
6. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Hatakeyama H; Akita H; Kogure K; Oishi M; Nagasaki Y; Kihira Y; Ueno M; Kobayashi H; Kikuchi H; Harashima H Gene Ther; 2007 Jan; 14(1):68-77. PubMed ID: 16915290 [TBL] [Abstract][Full Text] [Related]
7. Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system. Sakurai Y; Hatakeyama H; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H Biol Pharm Bull; 2009 May; 32(5):928-32. PubMed ID: 19420766 [TBL] [Abstract][Full Text] [Related]
8. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA. Sakurai Y; Hatakeyama H; Sato Y; Akita H; Takayama K; Kobayashi S; Futaki S; Harashima H Biomaterials; 2011 Aug; 32(24):5733-42. PubMed ID: 21605898 [TBL] [Abstract][Full Text] [Related]
9. Reprint of: Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation. Akita H; Kogure K; Moriguchi R; Nakamura Y; Higashi T; Nakamura T; Serada S; Fujimoto M; Naka T; Futaki S; Harashima H J Control Release; 2011 Jan; 149(1):58-64. PubMed ID: 20826039 [TBL] [Abstract][Full Text] [Related]
10. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery. Wang XL; Xu R; Lu ZR J Control Release; 2009 Mar; 134(3):207-13. PubMed ID: 19135104 [TBL] [Abstract][Full Text] [Related]
11. Enhanced gene expression by a novel stearylated INF7 peptide derivative through fusion independent endosomal escape. El-Sayed A; Masuda T; Khalil I; Akita H; Harashima H J Control Release; 2009 Sep; 138(2):160-7. PubMed ID: 19465073 [TBL] [Abstract][Full Text] [Related]
12. Advantages of ethanol dilution method for preparing GALA-modified liposomal siRNA carriers on the in vivo gene knockdown efficiency in pulmonary endothelium. Kusumoto K; Akita H; Santiwarangkool S; Harashima H Int J Pharm; 2014 Oct; 473(1-2):144-7. PubMed ID: 24998506 [TBL] [Abstract][Full Text] [Related]
13. PEGylation of the GALA Peptide Enhances the Lung-Targeting Activity of Nanocarriers That Contain Encapsulated siRNA. Santiwarangkool S; Akita H; Nakatani T; Kusumoto K; Kimura H; Suzuki M; Nishimura M; Sato Y; Harashima H J Pharm Sci; 2017 Sep; 106(9):2420-2427. PubMed ID: 28483420 [TBL] [Abstract][Full Text] [Related]
14. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Hatakeyama H; Akita H; Harashima H Adv Drug Deliv Rev; 2011 Mar; 63(3):152-60. PubMed ID: 20840859 [TBL] [Abstract][Full Text] [Related]
15. Functional improvement of an IRQ-PEG-MEND for delivering genes to the lung. Ishitsuka T; Akita H; Harashima H J Control Release; 2011 Aug; 154(1):77-83. PubMed ID: 21619903 [TBL] [Abstract][Full Text] [Related]
16. Ornithine and tryptophan analogs as efficient polycations for short interference RNA delivery to tumor cells. Sato Y; Hatakeyama H; Harashima H Biol Pharm Bull; 2010; 33(7):1246-9. PubMed ID: 20606322 [TBL] [Abstract][Full Text] [Related]
17. [Development of an efficient short interference RNA (siRNA) delivery system with a new pH-sensitive cationic lipid]. Sato Y; Hatakeyama H; Hyodo M; Akita H; Harashima H Yakugaku Zasshi; 2012; 132(12):1355-63. PubMed ID: 23208041 [TBL] [Abstract][Full Text] [Related]
18. Octaarginine-modified multifunctional envelope-type nano device for siRNA. Nakamura Y; Kogure K; Futaki S; Harashima H J Control Release; 2007 Jun; 119(3):360-7. PubMed ID: 17478000 [TBL] [Abstract][Full Text] [Related]
19. A novel IRQ ligand-modified nano-carrier targeted to a unique pathway of caveolar endocytic pathway. Mudhakir D; Akita H; Tan E; Harashima H J Control Release; 2008 Jan; 125(2):164-73. PubMed ID: 18054812 [TBL] [Abstract][Full Text] [Related]